Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Gold Standard Diagnostics Horsham is the current operating name for the former Eurofins Abraxis business in Horsham, Pennsylvania. The company develops, manufactures, and markets rapid test kits, reagents, standards, QC materials, and related laboratory equipment for environmental, food, and life sciences applications, with additional ISO 13485-certified in vitro diagnostic capabilities. Its portfolio is focused on analytical and diagnostic testing products rather than therapeutic drug development, including assays for algal toxins, glyphosate, GMOs, pesticides, bacterial toxins, veterinary residues, and related analytes. The business became Eurofins Abraxis after Abraxis, Inc. joined Eurofins Technologies in November 2017, and it was rebranded to Gold Standard Diagnostics beginning December 1, 2022. It operates as part of the broader Eurofins/Gold Standard Diagnostics network serving industrial, research, government, and diagnostic customers.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Gold Standard Diagnostics Horsham.